Rena Therapeutics Inc.
PrivateLast Round
M&A
Nov 21, 2019
Est. Valuation
$16.62M
Total Funding Raised
$10.36M
Company Overview
Rena Therapeutics Inc. is a biotechnology company that develops Heteroduplex Oligonucleotide (HDO) technology as a platform for nucleic acid medicine drug discovery.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Data as a Service, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Rena Therapeutics Inc. Comparables
Compare Rena Therapeutics Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Liid Pharmaceuticals, Inc. | 81% | |
| Bonac Corporation | 73% | |
| NapaJen Pharma, Inc. | 72% | |
Rena Therapeutics Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | Nov 21, 2019 | ||||
| Series B | Jun 30, 2017 | ||||
| Series A | Apr 20, 2015 |
Rena Therapeutics Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovation Network Corporation of Japan | Series A, Series B |
| DBJ Capital | Series A |
Rena Therapeutics Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Rena Therapeutics Inc.'s valuation, stock price, and market status.